Given that the sample size was too small to draw any conclusions, cohort 4 is currently enrolling patients to evaluate zolbetuximab in combination with FOLFOX and nivolumab as first-line therapy in patients with intermediate-to-high CLDN18.2-positive HER2-negative metastatic GC/GEJC. The gene discussed is ERBB2; the disease is gastric cancer.